NDA 214410 · Genentech INC
Xofluza
Baloxavir Marboxil · Oral
Last checked: Nov 20, 2026Latest source record: May 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Aug 11, 2022
Approved uses
5
Original approval plus efficacy supplements
Registered trials
21
14 Phase 3, 7 recruiting
FAERS reports
2,319
1,231 serious, 136 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 15, 2025.
XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for: Treatment of acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications . ( 1.1 ) Post-exposure prophylaxis of influenza in patients 5 years of age and older following contact with an individual who has influenza. ( 1.2 ) Limitations of Use Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA. ( 1.3 ) 1.1 Treatment of Influenza XOFLUZA is indicated for treatment of acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications 1 [see Clinical Studies (14.1 , 14.2 , and 14.3 ]. 1.2 Post-Exposure Prophylaxis of Influenza XOFLUZA is indicated for post-exposure prophylaxis of influenza in persons 5 years of age and older following contact with an individual who has influenza [see Clinical Studies (14.4) ]. 1.3 Limitations of Use Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA [see Warnings and Precautions (5.2) , Microbiology (12.4)...
Mechanism: Baloxavir marboxil is an antiviral drug with activity against influenza virus [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 30, 2025 Supplement 8 · Efficacy LetterLabel
- Dec 19, 2024 Supplement 7 · Efficacy LetterLabel
- Mar 1, 2024 Supplement 6 · Efficacy LabelLetter
- Aug 11, 2022 Original approval · Efficacy LabelLetterReview
- Nov 23, 2020 Original approval · Type 3 - New Dosage Form LabelLetterReview
3 products under this application
- XOFLUZA · BALOXAVIR MARBOXIL 30MG/PACKET · FOR SUSPENSION, ORAL · Prescription
- XOFLUZA · BALOXAVIR MARBOXIL 40MG/PACKET · FOR SUSPENSION, ORAL · Prescription
- XOFLUZA · BALOXAVIR MARBOXIL 2MG/ML · FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Baloxavir Marboxil" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in HouseholdsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03969212 · 4,138 participants · Start Oct 10, 2019 · Primary completion May 10, 2024
Drug: Baloxavir Marboxil; Placebo · For: Influenza
Sites: Birmingham, Alabama; Pelham, Alabama; Phoenix, Arizona · 142 sites in all
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05648448 · 3,000 participants (planned) · Start Feb 22, 2023 · Primary completion Jan 1, 2027
Drug: Oseltamivir; Favipiravir and 8 more · For: Influenza; Influenza, Human
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 4 sites in all
- Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza ComplicationsPivotal-lookingCompleted
ShionogiIndustry
NCT02949011 · 2,184 participants · Start Jan 11, 2017 · Primary completion Apr 12, 2018
Drug: Baloxavir Marboxil; Placebo to Baloxavir Marboxil and 2 more · For: Influenza
- A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With InfluenzaPivotal-lookingCompleted
ShionogiIndustry
NCT02954354 · 1,436 participants · Start Dec 8, 2016 · Primary completion Apr 4, 2017
Drug: Baloxavir Marboxil; Placebo to Baloxavir Marboxil and 2 more · For: Influenza
- A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household ContactsPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06094010 · 1,100 participants (planned) · Start Nov 22, 2023 · Primary completion May 11, 2027
Drug: Baloxavir Marboxil · For: Influenza
Sites: Birmingham, Alabama; Harrisburg, Arkansas; Miami, Florida · 52 sites in all
- A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Influenza APivotal-lookingStatus unknown
Capital Medical UniversityAcademic, hospital or other
NCT06205641 · 584 participants (planned) · Start Jan 2024 · Primary completion Jun 2024
Drug: Xuanfei Baidu Granule Placebo; Xuanfei Baidu Granule and 1 more · For: Influenza A
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event547
- off label use427
- intentional product use issue283
- diarrhoea136
- vomiting132
- pneumonia115
- drug ineffective90
- nausea75
- rash70
- hyperpyrexia68
- headache64
- influenza60
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 24 |
| 2019 | 814 |
| 2020 | 652 |
| 2021 | 56 |
| 2022 | 84 |
| 2023 | 161 |
| 2024 | 123 |
| 2025 | 250 |
| 2026 | 154 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xofluza (Baloxavir Marboxil)
2024 spending
$1.2M
Beneficiaries
7,548
7,723 claims
Per beneficiary
$166
$158.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,871,274 |
| 2021 | $644,817 |
| 2022 | $2,414,068 |
| 2023 | $1,027,972 |
| 2024 | $1,249,680 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG, Sugaya N, Hirotsu N, et al. · N Engl J Med 2018 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza.
Monto AS, Kuhlbusch K, Bernasconi C, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis.
Shiraishi C, Kato H, Hagihara M, et al. · J Infect Chemother 2024 · Systematic Review, Meta-Analysis
- Clinical efficacy and Safety of Baloxavir Marboxil compared with Oseltamivir against influenza virus in children: A systematic review and meta-analysis.
Zhu L, Zhong L, Huang G · PLoS One 2025 · Meta-Analysis, Systematic Review
- Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Ison MG, Portsmouth S, Yoshida Y, et al. · Lancet Infect Dis 2020 · Clinical Trial, Phase III, Multicenter Study
- Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
Kumar D, Ison MG, Mira JP, et al. · Lancet Infect Dis 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.